Mechanism of RAF isoform switching induced by oncogenic RAS in melanoma

Small GTPases

Volumn 2, Issue 5, 2011, Pages 289-292

  Dumaz, Nicolas ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

BRAF; CAMP; CRAF; ERK; Melanoma; PDE; RAS; Therapy

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; GSK 2118436; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN CRAF; PROTEIN NRAS; RAF PROTEIN; RAS PROTEIN; UNCLASSIFIED DRUG; VEMURAFENIB;

ARTICLE; BRAF GENE; CARCINOGENESIS; CRAF GENE; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE MUTATION; GENE SWITCHING; HUMAN; MELANOMA; MELANOMA CELL; MUTANT; NEGATIVE FEEDBACK; NRAS GENE; ONCOGENE RAS; PROTEIN BINDING; TUMOR GENE;

EID: 80054109895     PISSN: 21541248     EISSN: 21541256     Source Type: Journal    
DOI: 10.4161/sgtp.2.5.17814     Document Type: Article

References (34)

1. Lomas J, Martin-Duque P, Pons M, Quintanilla M. The genetics of malignant melanoma. Front Biosci 2008; 13:5071-93; PMID:18508571; http://dx.doi.org/10.2741/3065.
2. Cheli Y, Ohanna M, Ballotti R, Bertolotto C. Fifteenyear quest for microphthalmia-associated transcription factor target genes. Pigment Cell Melanoma Res 2009; 23:27-40.
3. Baillie GS, Scott JD, Houslay MD. Compartmentalisation of phosphodiesterases and protein kinase A: opposites attract. FEBS Lett 2005; 579:3264-70; PMID:15943971; http://dx.doi.org/10.1016/j.febslet.2005.03.089.
4. Houslay MD. Underpinning compartmentalized cAMP signalling through targeted cAMP breakdown. Trends Biochem Sci 2010; 35:91-100; PMID:19864144; http://dx.doi.org/10.1016/j.tibs.2009.09.007.
5. Maurer G, Tarkowski B, Baccarini M. Raf kinases in cancer-roles and therapeutic opportunities. Oncogene 2011; 30:3477-88; PMID:21577205; http://dx.doi.org/10.1038/onc.2011.160.
6. Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol 2004; 5:875-85; PMID:15520807; http://dx.doi.org/10.1038/nrm1498.
7. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 2007; 445:851-7; PMID:17314971; http://dx.doi.org/10.1038/nature05661.
8. Platz A, Egyhazi S, Ringborg U, Hansson J. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol Oncol 2008; 1:395-405; PMID:19383313; http://dx.doi.org/10.1016/j.molonc.2007.12.003.
9. Dumaz N, Marais R. Integrating signals between cAMP and the RAS/RAF/MEK/ERK signaling pathways. Based on the anniversary prize of the Gesellschaft fur Biochemie und Molekularbiologie Lecture delivered on 5 July 2003 at the Special FEBS Meeting in Brussels. FEBS J 2005; 272:3491-504; PMID:16008550; http://dx.doi.org/10.1111/j.1742-4658.2005.04763.x.
10. Dumaz N, Hayward R, Martin J, Ogilvie L, Hedley D, Curtin JA, et al. In Melanoma, RAS Mutations Are Accompanied by Switching Signaling from BRAF to CRAF and Disrupted Cyclic AMP Signaling. Cancer Res 2006; 66:9483-91; PMID:17018604; http://dx.doi.org/10.1158/0008-5472.CAN-05-4227.
11. Emuss V, Garnett M, Mason C, Marais R. Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF. Cancer Res 2005; 65:9719-9726; PMID:16266992; http://dx.doi.org/10.1158/0008-5472.CAN-05-1683.
12. Marquette A, Bagot M, Bensussan A, Dumaz N. Recent discoveries in the genetics of melanoma and their therapeutic implications. Arch Immunol Ther Exp (Warsz) 2007; 55:363-372; PMID:18060370; http://dx.doi.org/10.1007/s00005-007-0043-5.
13. Garnett MJ, Marais R. Guilty as charged; B-RAF is a human oncogene. Cancer Cell 2004; 6:313-319; PMID:15488754; http://dx.doi.org/10.1016/j.ccr.2004.09.022.
14. Garnett MJ, Rana S, Paterson H, Barford D, Marais R. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol Cell 2005; 20:963-9; PMID:16364920; http://dx.doi.org/10.1016/j.molcel.2005.10.022.
15. Smalley KS, Xiao M, Villanueva J, Nguyen TK, Flaherty KT, Letrero R, et al. CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene 2009; 28:85-94; PMID:18794803; http://dx.doi.org/10.1038/onc.2008.362.
16. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363:809-19; PMID:20818844; http://dx.doi.org/10.1056/NEJMoa1002011.
17. Vultur A, Villanueva J, Herlyn M. Targeting BRAF in advanced melanoma: a first step toward manageable disease. Clin Cancer Res 2011; 17:1658-63; PMID:21447722; http://dx.doi.org/10.1158/1078-0432.CCR-10-0174.
18. Jiang CC, Lai F, Thorne RF, Yang F, Liu H, Hersey P, et al. MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720. Clin Cancer Res 2011; 17:721-30; PMID:21088259; http://dx.doi.org/10.1158/1078-0432.CCR-10-2225.
19. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010; 18:683-995; PMID:21156289; http://dx.doi.org/10.1016/j.ccr.2010.11.023.
20. Paraiso KHT, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, et al. PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression. Cancer Res 2011; 71:2750-60; PMID:21317224; http://dx.doi.org/10.1158/0008-5472.CAN-10-2954.
21. Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011; 29:3085-3096; PMID:21383288; http://dx.doi.org/10.1200/JCO.2010.33.2312.
22. Marquette A, Andre J, Bagot M, Bensussan A, Dumaz N. ERK and PDE4 cooperate to induce RAF isoform switching in melanoma. Nat Struct Mol Biol 2011; 18:584-591; PMID:21478863; http://dx.doi.org/10.1038/nsmb.2022.
23. Brummer T, Naegele H, Reth M, Misawa Y. Identification of novel ERK-mediated feedback phosphorylation sites at the C-terminus of B-Raf. Oncogene 2003; 22:8823-34; PMID:14654779; http://dx.doi.org/10.1038/sj.onc.1207185.
24. Ritt DA, Monson DM, Specht SI, Morrison DK. Impact of Feedback Phosphorylation and Raf Heterodimerization on Normal and Mutant B-Raf Signaling. Mol Cell Biol 2010; 30:806-819; PMID:19933846; http://dx.doi.org/10.1128/MCB.00569-09.
25. Dougherty MK, Muller J, Ritt DA, Zhou M, Zhou XZ, Copeland TD, et al. Regulation of Raf-1 by direct feedback phosphorylation. Mol Cell 2005; 17:215-224; PMID:15664191; http://dx.doi.org/10.1016/j.molcel.2004.11.055.
26. Halaban R, Zhang W, Bacchiocchi A, Cheng E, Parisi F, Ariyan S, et al. PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells. Pigment Cell Melanoma Res 2010; 23:190-200; PMID:20149136; http://dx.doi.org/10.1111/j.1755-148X.2010.00685.x.
27. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010; 464:431-435; PMID:20130576; http://dx.doi.org/10.1038/nature08833.
28. Heidorn SJ, Milagre M, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, et al. Kinase- Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF. Cell 2010; 140:209-21; PMID:20141835; http://dx.doi.org/10.1016/j.cell.2009.12.040.
29. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimmers and ERK signalling in cells with wild-type BRAF. Nature 2010; 464:427-430; PMID:20179705; http://dx.doi.org/10.1038/nature08902.
30. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006; 439:358-362; PMID:16273091; http://dx.doi.org/10.1038/nature04304.
31. O'Byrne PM, Gauvreau G. Phosphodiesterase-4 inhibition in COPD. Lancet 2009; 374:665-667; PMID:19716944; http://dx.doi.org/10.1016/S0140-6736(09)61538-5.
32. Sengupta R, Sun T, Warrington NM, Rubin JB. Treating brain tumors with PDE4 inhibitors. Trends Pharmacol Sci 2011; 32:337-344; PMID:21450351; http://dx.doi.org/10.1016/j.tips.2011.02.015.
33. Blasco RB, Francoz S, Santamaria D, Canamero M, Dubus P, Charron J, et al. C-Raf, but not B-Raf, is essential for development of K-Ras oncogenedriven non-small cell lung carcinoma. Cancer Cell 2011; 19:652-663; PMID:21514245; http://dx.doi.org/10.1016/j.ccr.2011.04.002.
34. Karreth FA, Frese KK, DeNicola GM, Baccarini M, Tuveson DA. C-Raf Is Required for the Initiation of Lung Cancer by K-RasG12D. Cancer Discovery 2011; 1:128-123. http://dx.doi.org/10.1158/2159-8290.CD-10-0044.